Clene's ALS Drug Increases Survival by 70% in Mid-stage Study

Clene's ALS Drug Increases Survival by 70% in Mid-stage Study

Submitted by admin on July 14, 2022 - 7:54pm
Source: 
BioSpace
News Tags: 
Clene
ALS
clinical trials
Headline: 
Clene's ALS Drug Increases Survival by 70% in Mid-stage Study
snippet: 

Shares of Clene, Inc. surged Thursday after the company released “golden” data from an interim analysis of a Phase II study showing that its add-on treatment, CNM-Au8, improved survival in patients with amyotrophic lateral sclerosis (ALS) by 70%.

Do Not Allow Advertisers to Use My Personal information